Exelixis, Inc. (EXEL): Price and Financial Metrics


Exelixis, Inc. (EXEL)

Today's Latest Price: $17.82 USD

0.17 (0.96%)

Updated Dec 13 6:55pm

Add EXEL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 325 in Biotech

See all "A" rated Strong Buy stocks

EXEL Stock Summary

  • With a price/earnings ratio of 7.98, Exelixis Inc P/E ratio is greater than that of about only 10.07% of stocks in our set with positive earnings.
  • For EXEL, its debt to operating expenses ratio is greater than that reported by just 11.58% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.11 for Exelixis Inc; that's greater than it is for only 8.07% of US stocks.
  • Stocks that are quantitatively similar to EXEL, based on their financial statements, market capitalization, and price volatility, are PTN, ACIA, SLAB, NVMI, and MEET.
  • Visit EXEL's SEC page to see the company's official filings. To visit the company's web site, go to www.exelixis.com.
EXEL Daily Price Range
EXEL 52-Week Price Range

EXEL Stock Price Chart More Charts


EXEL Price/Volume Stats

Current price $17.82 52-week high $25.31
Prev. close $17.65 52-week low $15.02
Day low $17.68 Volume 3,079,200
Day high $18.32 Avg. volume 3,073,385
50-day MA $16.61 Dividend yield N/A
200-day MA $19.87 Market Cap 5.41B

Exelixis, Inc. (EXEL) Company Bio


Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. The company was founded in 1994 and is based in San Francisco, California.





EXEL Latest News Stream


Event/Time News Detail
Loading, please wait...

EXEL Latest Social Stream


Loading social stream, please wait...

View Full EXEL Social Stream

EXEL Price Returns

1-mo 7.93%
3-mo -8.00%
6-mo -15.02%
1-year -15.26%
3-year 6.13%
5-year 1,210.29%
YTD -9.41%
2018 -35.30%
2017 103.89%
2016 164.36%
2015 291.67%
2014 -76.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4873 seconds.